首页> 外文期刊>Open Veterinary Journal >Innocuity and immune response to Brucella melitensis Rev.1 vaccine in camels ( Camelus dromedarius )
【24h】

Innocuity and immune response to Brucella melitensis Rev.1 vaccine in camels ( Camelus dromedarius )

机译:骆驼(Camelus dromedarius)对布鲁氏布鲁氏菌Rev.1疫苗的无毒性和免疫反应。

获取原文
       

摘要

A field trial was conducted in a camel brucellosis-free herd to evaluate antibody response to the Brucella melitensis Rev.1 vaccine in camels and assess shedding of the vaccine strain in milk. Twenty eight camels were divided into?four groups according to their age and vaccination route. Groups A (n=3) and B (n=3) consisted of non-pregnant?lactating female camels, vaccinated through subcutaneous and conjunctival routes, respectively. Groups C (n=10)?consisted of 8-11 months old calves vaccinated through conjunctival route. The rest of the herd (n=12) composed of?female and young camels were not vaccinated and were considered as the control group. Each animal from groups?A, B and C was given the recommended dose of 2 x 109 colony forming units of Rev.1 vaccine irrespective of age or?route of vaccination. Blood samples were collected from all the animals at the time of vaccination and at weekly,?bi-weekly and monthly interval until 32 weeks post vaccination and from controls at weeks 8 and 24. The?serological tests used were modified Rose Bengal Test, sero agglutination test, and an indirect Enzyme Linked?Immunosorbent Assay. Milk samples were collected from all vaccinated female camels and tested for the presence?of Rev.1 vaccine strain. Most vaccinated animals started to show an antibody response at week 2 and remained?positive until week 16. By week 20 post-vaccination all animals in the three groups were tested negative for Brucella antibodies. Bacteriological analysis of milk samples did not allow any isolation of Brucella melitensis . All?samples were found Brucella negative in PCR analysis. The results of this study indicate that the Rev.1 vaccine?induces seroconversion in camels. Rev.1 vaccine strain is not excreted in the milk of camels. These findings are?promising as to the safe use of the Rev.1 vaccine in camels.
机译:在无骆驼病的牛群中进行了现场试验,以评估骆驼对布鲁氏布鲁氏菌Rev.1疫苗的抗体反应,并评估疫苗菌株在牛奶中的脱落。根据骆驼的年龄和疫苗接种途径,将其分为28组。 A组(n = 3)和B组(n = 3)由未妊娠的雌性骆驼组成,分别通过皮下和结膜途径接种。 C组(n = 10)由结膜途径接种的8-11个月大的小牛组成。其余的由雌,幼骆驼组成的牛群(n = 12)没有接种疫苗,被认为是对照组。 A,B和C组的每只动物均建议使用Rev.1疫苗2 x 10 9 菌落形成单位的推荐剂量,而不论其年龄或接种途径如何。在接种疫苗时,每周,每两周和每月间隔直至接种后32周从所有动物中采集血样,并在第8和24周时从对照组中采集血样。凝集试验和间接酶联免疫吸附测定。从所有接种过的雌性骆驼中收集牛奶样品,并测试Rev.1疫苗株的存在。大多数接种疫苗的动物在第2周开始表现出抗体反应,并一直保持阳性直到第16周。到接种疫苗后第20周,三组中的所有动物的布鲁氏菌抗体均呈阴性。牛奶样品的细菌学分析不能分离布鲁氏菌。在PCR分析中发现所有样品均为布鲁氏菌阴性。这项研究的结果表明,Rev.1疫苗可诱导骆驼的血清转化。 Rev.1疫苗株不在骆驼的乳汁中排出。这些发现对于骆驼中Rev.1疫苗的安全使用是有前途的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号